article thumbnail

Contamination Trends & Proposed Solutions

ISPE

5 , 8 Compounding pharmacies were commonly mentioned as sources of microbial cross-contamination, especially in the US. 9 , 15 This has led to compounding pharmacies completing high-volume activities such as mass repackaging, thereby increasing the risk of cross-contamination. Compounding Pharmacies: Who Is in Charge?”

article thumbnail

Top Performing Drug of 2021 - Trulicity (February Edition)

PharmaShots

In the US, Trulicity is protected by a compound patent (2027) and by biologics data protection (2026).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Considerations for a Decentralized Manufacturing Paradigm

ISPE

Examples include platforms as small as autonomous units placed within a facility and mobile production trailers for compounding to platforms as large as a prefabricated, self-contained GMP facility. Nature Communications 12, no. 3 , 27 Advantages POD increases manufacturing flexibility, speed, and consistency. 3 (2020):e2970.

article thumbnail

High biologics demand spurs need for greater contract manufacturing

Pharmaceutical Technology

Meanwhile, the Indian biologics market is expected to grow to $12 billion by 2025, with a compound annual growth rate (CAGR) of 22%. GlobalData forecasts Biologics to significantly overtake sales of small molecules by $120 billion by 2027. Please check your email to download the Whitepaper.

article thumbnail

Empress Therapeutics emerges with $50m to fund small molecule development

Pharmaceutical Technology

Dr. Doug Cole, co-founder of Empress Therapeutics, explained that Chemilogics links gene pathways to small molecule compounds, allowing for drugs with the versatility of small molecules without the unpredictable, expensive, and time-consuming discovery process. Murray KcKinnon, PhD He joined Empress as chief scientific officer.